The monoclonal antibody has become instrumental for the treatment of multiple myeloma.

In this sequence, monoclonal antibodies are seen targeting CD38, a protein commonly expressed on the surface of cancerous plasma cells.

Activation of the complement system triggers the formation of pores in the cellular membrane, leading to cell death.

A goal for this sequence was to explore a visual approach that resembled a deep sea look & feel, including planktonic soft-bodied organisms and other invertebrate animals that live near the ocean floor.

View animation >>

Tagged: antibodies, antibody, antigen, biology class, blood cancer, cancer, CD38, CD38 antibodies, hybrid medical, immune system, mAb, medical animation, medical illustration, medical marketing, medical visualization, monoclonal, multiple myeloma, myeloid, pharmaceutical animation, science, science art, science visuals, scientific animation

Sequence from project that provides insight on the role aberrant DNA methylation has in the abnormalities responsible for cancer cell growth, especially hematological malignancies such as leukemia, lymphoma, and multiple myeloma.

In this sequence, we begin with a view of “normal” DNA methylation, and then change to a view of hypermethylation underway.

Eventually, decitabine – a hypomethylating agent – can be seen moving into place and blocking DNA methyltransferase (DNMT), leading to the degradation of DNMT and eventual hypomethylation.

Targeting DNA methylation with DNA hypomethylating agents (HMAs) acts to reprogram tumor cells to a more normal-like state.

View animation >>

Tagged: aberrant DNA methylation patterns, abnormal methylation, biomedical communications, biotech, cancer, cedazuridine, cytidine deaminase, decitabine, DNA, DNA methylation, DNA methyltransferase inhibitors, DNMT degradation, epigenetic cancer therapy, gene expression, genetic mutations, genetics, hematological malignancies, histones, hybrid medical, hypermethylation, hypomethylating agents, hypomethylation, leukemia, medical animation, medical marketing, nucleosome, oncology, scientific animation

A few selected segments from a 6-minute animation created for a first-in-class B-cell maturation antigen (BCMA)-directed personalized immunotherapy called chimeric antigen receptor (CAR) T-cell therapy.

In this CAR T therapy, the T cells are engineered to target a protein called BCMA, which is found in abundance on multiple myeloma cells, but is absent from nearly all normal cells.

View animation >>

Tagged: (CAR) T-cell therapy, antigens, biology, biotechnology, cancer, cancer research, cancer treatment, CAR T, CAR T cell animation, CAR T therapy, CAR T-cell animation, car-t cell therapy, chimeric antigen receptor, chimeric antigen receptor animation, gene therapy, hybrid medical, immune health, immunotherapy, medical animation, Medical science, medical visualisation, pharma, scientific animation, T cells, visual science

Activated T cells of the immune system targeting and destroying tumor cells. Once lysis occurs, the T cell moves to another cancer cell and repeats the process.

Sequence created for program that explores the impact of immunotherapies for lung cancer.

View animation >>

Tagged: biology, cancer, hybrid medical, immune system, immunology, immunotherapy, killer cells, medical animation, science visuals, scientific animation, tumor cells

Watch a chimeric antigen receptor (CAR) sprout from the surface of a genetically re-engineered white blood cell.

A chimeric antigen receptor (CAR) sprouts from the surface of a genetically re-engineered white blood cell.

View animation >>

Tagged: antigens, biology, biomedical communications, cancer, cancer treatment, car-t cell therapy, gene, hybrid medical animation, Minneapolis Minnesota, visual science

Tagged: antibodies, antibody, antibody animation, antibody drug conjugate, biology, biopharmaceutical drugs, biotechnology, Biotherapeutic, cancer, cancer immunotherapy, cell biology, drug payload, hybrid medical, hybrid medical animation, immunotherapy, medical animation, Medical science, medical visualisation, medicine, monoclonal, monoclonal antibodies, pharma, science, science art, science visuals, scientific animation, therapeutic, visual science

Sequence from 5-minute MOA that provides insight and details for a monoclonal antibody (mAb) designed to induce programmed tumor cell death (apoptosis) and immunomodulatory activity.

For this mechanism of action video, our task was to create a science story that would depict several key features: how the mAb finds and binds to myeloma cells and exposes them for elimination, how it boosts cells of the immune system, and how this targeted immunotherapy can kill myeloma cells directly.

View animation >>

Tagged: antibody, biomedical communications, biotech, blood cancer, cancer, cancer immunotherapy, cancer treatment, CD38, hybrid medical, immunotherapy, leukemia, lymphoma, medical animation, medical marketing, monoclonal antibodies, multiple myeloma, myeloid, myeloma awareness, oncology, scientific animation, visual science